A pooled analysis of the cardiac events in the trastuzumab adjuvant trials

Background Trastuzumab-associated cardiotoxicity remains an issue for patients with HER2-positive breast cancer. This pooled analysis of 3 adjuvant trials investigated the incidence, timing, impact on treatment completion, and risk factors for trastuzumab-associated cardiotoxicity. Methods This is a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2020-01, Vol.179 (1), p.161-171
Hauptverfasser:	de Azambuja, Evandro, Ponde, Noam, Procter, Marion, Rastogi, Priya, Cecchini, Reena S., Lambertini, Matteo, Ballman, Karla, Aspitia, Alvaro Moreno, Zardavas, Dimitrios, Roca, Lise, Gelber, Richard D., Piccart-Gebhart, Martine, Suter, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Analysis Anthracycline Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Body mass index Breast cancer Breast Neoplasms - drug therapy Cancer Cancer research Cardiac patients Cardiotoxicity Care and treatment Case-Control Studies Chemotherapy Clinical Trial Clinical trials Congestive heart failure ErbB-2 protein Female Heart Diseases - chemically induced Heart Diseases - epidemiology Humans Immunotherapy Incidence Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Oncology Pertuzumab Randomized Controlled Trials as Topic Risk factors Targeted cancer therapy Trastuzumab Trastuzumab - administration & dosage Trastuzumab - adverse effects Treatment Outcome Ventricle
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!